Market Overview

Senseonics and Beta Bionics Partner on Development of the Bionic Pancreas System

Share:

Long-term, implantable continuous glucose sensor to be integrated with
bionic pancreas system

Senseonics Holdings, Inc. (NYSE-American: SENS), a medical technology
company focused on the development and commercialization of
transformative glucose monitoring products, and Beta Bionics, a medical
technology company leveraging machine learning artificial intelligence
to develop and commercialize the world's first autonomous bionic
pancreas, today announced that they have entered into a development
agreement to integrate glucose data from the Eversense® Continuous
Glucose Monitoring (CGM) system into the iLet Bionic Pancreas system.

The Eversense CGM system is a long-term, implantable continuous glucose
monitoring system that continually measures interstitial fluid glucose
levels and wirelessly sends the readings to a smartphone application.
The iLet Bionic Pancreas system is a dual-chamber, autonomous, infusion
pump that mimics a biological pancreas by automatically and autonomously
adapting insulin and glucagon dosing to meet the individual needs of a
person with diabetes.

"We are very excited to partner with Beta Bionics to integrate our
long-term glucose sensor with the bionic pancreas system," said Tim
Goodnow, President and CEO of Senseonics. "The combination of these two
technologies could create a unique option for increased simplicity,
convenience and confidence in diabetes management. We are pleased to be
working with the Beta Bionics team as they advance a real breakthrough
for people with diabetes."

"Senseonics has generated impressive clinical data demonstrating the
remarkable accuracy of their Eversense CGM system and providing a
categorically different CGM alternative for people with diabetes," said
Ed Damiano, President and CEO of Beta Bionics. "We believe that only
highly accurate, reliable and safe sensors are suitable for driving
automated insulin delivery systems. Based on clinical data from multiple
clinical studies, the Eversense CGM system appears to meet these high
standards. We are excited to partner with Senseonics to help make the
iLet Bionic Pancreas system a platform of choice for people with
diabetes – one that will ultimately allow people to choose between
multiple CGMs, to choose between multiple insulin types, and to choose
glucagon."

Under this development agreement, Beta Bionics will work with Senseonics
to integrate the Eversense CGM system with the iLet, so that real-time
Eversense data may serve as one CGM option to drive the fully autonomous
iLet Bionic Pancreas system.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics' first generation continuous glucose monitoring (CGM)
system, Eversense®, includes a small sensor, smart transmitter and
mobile application. Based on fluorescence sensing technology, the sensor
is designed to be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile device.
After insertion, the sensor is designed to continually and accurately
measure glucose levels. For more information on Senseonics, please visit www.senseonics.com.

About Beta Bionics

Beta Bionics is a for-profit Massachusetts public benefit corporation
founded in 2015 to commercialize the iLet, a revolutionary bionic
pancreas that is driven by machine-learning mathematical dosing
algorithms, which incorporate artificial intelligence to autonomously
control glycemia. These dosing algorithms were developed in the Damiano
Lab at Boston University and refined based on results from home-use
clinical trials in adults and children with T1D. Beta Bionics is a
Certified B Corporation™ whose founders—in addition to Ed
Damiano—include other parents of children with type 1 diabetes. Beta
Bionics is committed to acting in the best interests of the diabetes
community and to profoundly disrupting the diabetes medical device
industry by bringing the iLet to market as expeditiously and responsibly
as possible. Beta Bionics is pursuing regulatory approval of its
insulin-only bionic pancreas, which will be followed by its dual-hormone
system that will also administer a glucagon analog in order to raise
blood-sugar levels without the need to consume carbohydrates.

Beta Bionics is headquartered in Boston, Massachusetts with certain
operations in Irvine, California. For further information, please visit www.betabionics.com
or follow Beta Bionics Facebook, YouTube, Instagram, LinkedIn and
Twitter @BetaBionics.

Forward Looking Statements

Certain statements contained in this press release, other than
statements of fact that are independently verifiable at the date hereof,
may constitute "forward-looking statements." These forward-looking
statements reflect Senseonics' current views about its plans,
intentions, expectations, strategies and prospects, including statements
concerning the potential integration of the Eversense CGM system with
Beta Bionics' Bionic Pancreas and the potential benefits to patients of
the combination of these technologies. Although Senseonics believes that
its plans, intentions, expectations, strategies and prospects as
reflected in or suggested by those forward-looking statements are
reasonable, Senseonics can give no assurance that the plans, intentions,
expectations or strategies will be attained or achieved. Furthermore,
actual results may differ materially from those described in the
forward-looking statements and will be affected by a variety of risks
and factors that are beyond Senseonics' control. Other risks and
uncertainties are more fully described in the section entitled "Risk
Factors" in Senseonics' Annual Report on Form 10-K filed with the
Securities and Exchange Commission (SEC) on March 13, 2018, its
Quarterly Report on Form 10-Q filed with the SEC on May 10, 2018 and its
other SEC filings. Existing and prospective investors are cautioned not
to place undue reliance on these forward-looking statements, which speak
only as of the date hereof. The statements made in this press release
speak only as of the date stated herein, and subsequent events and
developments may cause Senseonics' expectations and beliefs to change.
While Senseonics may elect to update these forward-looking statements
publicly at some point in the future, Senseonics specifically disclaims
any obligation to do so, whether as a result of new information, future
events or otherwise, except as required by law.

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com